HOME >> BIOLOGY >> NEWS
Targeted therapy knocks out pediatric brain cancer in mice

Scientists have identified what may be the first nontoxic treatment for a subset of medulloblastoma, the most common type of malignant pediatric brain tumor. The finding is encouraging in that such precise, targeted therapies may someday replace traditional treatments that can have overwhelmingly negative side effects for pediatric cancer patients. The research is published in the September issue of Cancer Cell.

"Therapy for pediatric cancers of the central nervous system has not improved significantly in the last three decades," explains study author Dr. Tom Curran from St. Jude Children's Research Hospital in Memphis, Tennessee. "This is partly due to the absence of adequate model systems for testing novel therapies." Dr. Curran and colleagues used a mouse model of medulloblastoma that they had developed to examine whether selective inhibition of the Sonic Hedgehog (Shh) signaling pathway could interfere with the development and progression of the disease. Previous studies have implicated the Shh pathway in human medulloblastoma formation.

Treatment of the mice with a small molecule inhibitor of Shh, HhAntag, resulted in elimination of medulloblastoma. HhAntag administration was associated with the suppression of multiple genes expressed in medulloblastoma as well as reduced cell proliferation and an increase in tumor cell death. Importantly, high doses of HhAntag completely eradicated the tumors, and long-term treatment prolonged medulloblastoma-free survival. No toxic side effects of HhAntag treatment were observed in the mice.

The researchers conclude that the development of compounds that selectively block Shh may be an appropriate direction for designing effective, nontoxic treatments for medulloblastoma. "Ultimately, it is likely that success in treating cancer will require the use of several compounds in concert that target distinct pathways important for tumor cell growth. Our mouse studies with HhAntag offer the hope that suc
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
20-Sep-2004


Page: 1 2

Related biology news :

1. Targeted therapy for lung cancer patients shows promise in extending lives
2. Targeted immunotherapy eradicates cancer in mice
3. Targeted radiation to liver tumors spares tissue, improves quality of life
4. Targeted Genetics presents data on arthritis gene therapy
5. Targeted genetics presents promising data from cystic fibrosis clinical trial
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/17/2019)... ... , ... VISTAAR released ADVISORY Playbooks to help small and mid-level ... opinion to their internal strategies they formed for developing or launching new products or ... or planning to change their product elements and want to know the impact, introducing ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... (WMIS) focused on non-invasive real-time tracking of gene therapy and advances to decrease ... years (and most cases fatal) lysomal storage diseases (LSD) are among the most ...
(Date:9/8/2019)... ... September 06, 2019 , ... The Board ... have each authorized the respective companies to proceed with a proposed business combination. ... Nanosens brand representing a series of products leveraging the CRISPR-Chip technology. The ...
Breaking Biology News(10 mins):
(Date:10/8/2019)... ... 07, 2019 , ... Erchonia Corporation, the global leader in ... that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) ... of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia continues to ...
(Date:10/3/2019)... ... October 02, 2019 , ... Murrieta Genomics , the ... and venture capital companies in Silicon Valley at a special Life Science showcase ... will be held at the JJ Lake Business Center located at 340 E. Middlefield ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... of high-level X-ray methods using synchrotron-produced X-rays to study amorphous drug formulations. ... present “Synchrotron X-Ray Diffraction and Pair Distribution Function Analysis of Drug/Polymer Dispersions: ...
(Date:9/24/2019)... , ... September 24, 2019 , ... In the past ... research led by faculty at South Dakota School of Mines & Technology ... microbes that attach to surfaces to form a slimy and yet strong layer which ...
Breaking Biology Technology:
Cached News: